Spyre Therapeutics, Inc.
SYRE
$14.46
$0.332.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 93.69% | -- | -- | 153.54% | 489.75% |
| Gross Profit | -93.69% | -- | -- | -157.24% | -496.78% |
| SG&A Expenses | -23.46% | 24.04% | 75.23% | 145.72% | 177.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.27% | 66.62% | 138.68% | 151.39% | 147.05% |
| Operating Income | -28.27% | -66.62% | -147.91% | -154.04% | -149.21% |
| Income Before Tax | 10.90% | -72.08% | 82.11% | -137.43% | -236.35% |
| Income Tax Expenses | -- | 500.00% | -- | 188.89% | -100.00% |
| Earnings from Continuing Operations | 10.90% | -72.11% | 82.11% | -138.07% | -235.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.90% | -72.11% | 82.11% | -138.07% | -235.67% |
| EBIT | -28.27% | -66.62% | -147.91% | -154.04% | -149.21% |
| EBITDA | -27.88% | -66.06% | -151.95% | -158.32% | -154.32% |
| EPS Basic | -99.66% | 85.48% | 98.49% | 75.42% | 334.76% |
| Normalized Basic EPS | 75.55% | 89.42% | 95.67% | 75.48% | 15.37% |
| EPS Diluted | -99.66% | 85.48% | 98.49% | 75.42% | 334.76% |
| Normalized Diluted EPS | 75.55% | 89.42% | 95.67% | 75.48% | 15.37% |
| Average Basic Shares Outstanding | 254.05% | 1,085.18% | 1,085.48% | 868.38% | 309.01% |
| Average Diluted Shares Outstanding | 254.05% | 1,085.18% | 1,085.48% | 868.38% | 309.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |